We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood Test Could Predict Relapse of Autoimmune Blood Vessel Disease

By LabMedica International staff writers
Posted on 25 Apr 2025

Neutrophils, once believed to be uniform in nature, have been discovered to exhibit significant diversity. More...

These immune cells, which play a crucial role in fighting infections, are also implicated in autoimmune diseases. Now, new research has revealed that a specific subset of neutrophils can predict disease relapse early, potentially paving the way for more tailored treatment approaches.

A study published in Nature Communications and led by a multi-institutional research team from The University of Osaka (Osaka, Japan) explored the dominant cell types in the blood of patients at the early stages of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. This disease, caused by inflammation in the blood vessels, can lead to organ dysfunction. The research team enrolled six patients and seven healthy controls for comparison, collecting around 180,000 white blood cells. These cells were subjected to single-cell analysis to examine their genetic characteristics and surface proteins. The analysis of the transcriptome and proteome revealed a significantly higher proportion of two specific neutrophil subpopulations in the patients compared to healthy individuals. Notably, the researchers found an increase in a highly activatable subset of neutrophils in the patients. These cells were found to be responsive to interferon-gamma (IFN-g), a key protein involved in inflammation.

Among the patients, those showing the highest expression of IFN-g response genes were found to have persistent vasculitis symptoms even after treatment, suggesting that this particular neutrophil subpopulation plays a role in the persistent nature of vasculitis. To further investigate, the team analyzed the levels of IFN-g in stored serum samples from 37 patients, some of whom were newly diagnosed and others who had undergone treatment. The results were striking. Of the 24 new-onset patients assessed, the six with the highest serum IFN-g concentrations all experienced relapses, suggesting that measuring IFN-g levels could serve as an early indicator of disease relapse. This research offers a deeper understanding of the immune mechanisms underlying ANCA-associated vasculitis and suggests potential new strategies for disease monitoring and treatment. By identifying specific neutrophil populations involved in disease progression, these findings could lead to more personalized therapies, ultimately improving outcomes for patients suffering from this rare but serious condition.

Related Links:
University of Osaka 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Immunofluorescence Analyzer
IFA System
New
Silver Member
Connectivity Solution
EKF Link
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Dr. Olivia Belbin, head of the Molecular Neurodegeneration Group at IR Sant Pau and study corresponding author, with Alba Cervantes (right), first author and IR Sant Pau researcher (Photo courtesy of IR Sant Pau)

Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome

Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.